Krebs Biochemicals & Industries Limited (KREBSBIO.BO)
INR 72.4
(1.7%)
INR 72.4
(1.7%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -82.72 Million INR | 42.46% |
| 2022 | -151.6 Million INR | 53.84% |
| 2021 | -328.39 Million INR | -95.09% |
| 2020 | -169.55 Million INR | 7.82% |
| 2019 | -182.65 Million INR | -93.58% |
| 2018 | -93.71 Million INR | -29.62% |
| 2017 | -85.14 Million INR | 8.18% |
| 2016 | -83.27 Million INR | 30.26% |
| 2015 | -110.95 Million INR | 0.0% |
| 2014 | - INR | 0.0% |
| 2011 | -13.49 Million INR | -118.85% |
| 2010 | 71.45 Million INR | 245.59% |
| 2009 | 20.72 Million INR | -95.14% |
| 2008 | -281.28 Million INR | 360.64% |
| 2007 | 92.53 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -21.96 Million INR | 25.51% |
| 2023 Q4 | -31.13 Million INR | -51.09% |
| 2023 FY | - INR | 42.46% |
| 2023 Q2 | -7.26 Million INR | 71.87% |
| 2023 Q1 | -25.82 Million INR | 41.75% |
| 2023 Q3 | -20.6 Million INR | -183.69% |
| 2022 Q3 | -29.63 Million INR | -82.19% |
| 2022 Q2 | -16.26 Million INR | 73.51% |
| 2022 Q1 | -61.39 Million INR | 31.28% |
| 2022 FY | - INR | 53.84% |
| 2022 Q4 | -44.33 Million INR | -49.61% |
| 2021 Q3 | -97.02 Million INR | -26.72% |
| 2021 Q2 | -76.56 Million INR | -17.86% |
| 2021 Q4 | -89.33 Million INR | 7.92% |
| 2021 FY | - INR | -95.09% |
| 2021 Q1 | -64.95 Million INR | -59.21% |
| 2020 Q3 | -55.94 Million INR | -84.72% |
| 2020 FY | - INR | 7.82% |
| 2020 Q4 | -40.8 Million INR | 27.07% |
| 2020 Q1 | -42.52 Million INR | -13.62% |
| 2020 Q2 | -30.28 Million INR | 28.78% |
| 2019 Q4 | -37.42 Million INR | 15.55% |
| 2019 FY | - INR | -93.58% |
| 2019 Q1 | -48.32 Million INR | -120.16% |
| 2019 Q2 | -50.67 Million INR | -4.87% |
| 2019 Q3 | -44.31 Million INR | 12.55% |
| 2018 Q2 | -5.42 Million INR | 80.38% |
| 2018 Q1 | -27.67 Million INR | 40.64% |
| 2018 FY | - INR | -29.62% |
| 2018 Q4 | -21.95 Million INR | 44.16% |
| 2018 Q3 | -39.3 Million INR | -624.06% |
| 2017 Q3 | 36.07 Million INR | 238.85% |
| 2017 Q1 | -36.43 Million INR | -385.15% |
| 2017 Q4 | -46.61 Million INR | -229.24% |
| 2017 FY | - INR | 8.18% |
| 2017 Q2 | -25.97 Million INR | 28.7% |
| 2016 Q2 | -24.91 Million INR | -19.37% |
| 2016 FY | - INR | 30.26% |
| 2016 Q3 | -25.94 Million INR | -4.12% |
| 2016 Q1 | -20.87 Million INR | 47.31% |
| 2016 Q4 | -7.51 Million INR | 71.05% |
| 2015 Q1 | -31.05 Million INR | 0.0% |
| 2015 FY | - INR | 0.0% |
| 2015 Q2 | -19.92 Million INR | 35.86% |
| 2015 Q3 | -23.13 Million INR | -16.12% |
| 2015 Q4 | -39.62 Million INR | -71.28% |
| 2014 FY | - INR | 0.0% |
| 2014 Q3 | -13.98 Million INR | 0.0% |
| 2013 Q2 | -18.3 Million INR | 0.0% |
| 2013 Q3 | -20.98 Million INR | -14.67% |
| 2012 Q3 | -34.13 Million INR | -4762.68% |
| 2012 Q2 | -702 Thousand INR | 0.0% |
| 2011 Q3 | -8.54 Million INR | 26.99% |
| 2011 FY | - INR | -118.85% |
| 2011 Q4 | 16.43 Million INR | 292.39% |
| 2011 Q2 | -11.69 Million INR | 0.0% |
| 2010 FY | - INR | 245.59% |
| 2009 FY | - INR | -95.14% |
| 2008 FY | - INR | 360.64% |
| 2008 Q4 | 257.39 Million INR | 0.0% |
| 2007 FY | - INR | 0.0% |
| 2007 Q4 | 13.94 Million INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 100.86% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 100.134% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 101.205% |
| Granules India Limited | 8.6 Billion INR | 100.962% |
| Indoco Remedies Limited | 2.64 Billion INR | 103.125% |
| Achyut Healthcare Limited | 524 Thousand INR | 15887.595% |
| Ajanta Pharma Limited | 12.56 Billion INR | 100.658% |
| Alkem Laboratories Limited | 24.19 Billion INR | 100.342% |
| Alpa Laboratories Limited | 86.12 Million INR | 196.052% |
| Brooks Laboratories Limited | 41.72 Million INR | 298.253% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 103.51% |
| Bajaj HealthCare Limited | 444.51 Million INR | 118.611% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | 105.593% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 100.094% |
| Eris Lifesciences Limited | 6.98 Billion INR | 101.184% |
| FDC Limited | 4.4 Billion INR | 101.879% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 100.729% |
| Gufic Biosciences Limited | 1.48 Billion INR | 105.588% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 101.206% |
| Ipca Laboratories Limited | 13.29 Billion INR | 100.622% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | 125.576% |
| Lasa Supergenerics Limited | -65.08 Million INR | -27.116% |
| Laurus Labs Limited | 8 Billion INR | 101.033% |
| Lupin Limited | 36.96 Billion INR | 100.224% |
| Mankind Pharma Limited | 28.09 Billion INR | 100.294% |
| Medicamen Biotech Limited | 245.66 Million INR | 133.675% |
| Medico Remedies Limited | 150.37 Million INR | 155.013% |
| Megasoft Limited | 284.73 Million INR | 129.054% |
| NATCO Pharma Limited | 18.79 Billion INR | 100.44% |
| Piramal Pharma Limited | 13.05 Billion INR | 100.634% |
| RPG Life Sciences Limited | 1.28 Billion INR | 106.455% |
| Sigachi Industries Limited | 883.39 Million INR | 109.365% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 100.06% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 101.769% |
| Syncom Formulations (India) Limited | 430.27 Million INR | 119.226% |
| Unichem Laboratories Limited | 742.35 Million INR | 111.144% |
| Wanbury Limited | 985.49 Million INR | 108.395% |
| Windlas Biotech Limited | 781.72 Million INR | 110.583% |
| ZIM Laboratories Limited | 462.09 Million INR | 117.903% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 100.147% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 97.783% |
| Divi's Laboratories Limited | 25.43 Billion INR | 100.325% |
| Hester Biosciences Limited | 539.47 Million INR | 115.335% |
| Procter & Gamble Health Limited | 3.01 Billion INR | 102.744% |
| Amrutanjan Health Care Limited | 682.53 Million INR | 112.12% |
| Bal Pharma Limited | 345.59 Million INR | 123.938% |
| Strides Pharma Science Limited | 3.76 Billion INR | 102.197% |
| Venus Remedies Limited | 711.8 Million INR | 111.622% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 102.116% |
| Nectar Lifesciences Limited | 1.56 Billion INR | 105.29% |
| Shilpa Medicare Limited | 2.58 Billion INR | 103.197% |
| Aarti Drugs Limited | 3.24 Billion INR | 102.547% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 103.174% |
| Suven Life Sciences Limited | -992.78 Million INR | 91.667% |
| Ind-Swift Limited | 1.06 Billion INR | 107.767% |
| Valiant Laboratories Limited | 12.73 Million INR | 749.399% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 100.886% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 97.068% |
| Themis Medicare Limited | 562.6 Million INR | 114.704% |
| Hikal Limited | 2.69 Billion INR | 103.073% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 100.236% |
| Sequent Scientific Limited | 549.8 Million INR | 115.047% |
| Novartis India Limited | 1.26 Billion INR | 106.518% |
| Wockhardt Limited | 1.08 Billion INR | 107.66% |
| Jubilant Pharmova Limited | 8 Billion INR | 101.033% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | 733.341% |
| Neuland Laboratories Limited | 4.74 Billion INR | 101.742% |
| Morepen Laboratories Limited | 1.72 Billion INR | 104.793% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | 128.782% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | 147.287% |